Natixis Regenxbio Inc. Transaction History
Natixis
- $16 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding RGNX
# of Institutions
191Shares Held
45.4MCall Options Held
184KPut Options Held
56.7K-
Black Rock Inc. New York, NY8.61MShares$70.7 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.79MShares$39.4 Million2.9% of portfolio
-
Jpmorgan Chase & CO New York, NY4.14MShares$34 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.99MShares$24.5 Million0.0% of portfolio
-
State Street Corp Boston, MA2.19MShares$17.9 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $355M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...